EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

PartnershipUpdated on 7 September 2026

WPD is seeking strategic pharmaceutical and biotechnology partners for co-development, licensing and commercialization of WPD401

About

WPD is seeking strategic pharmaceutical and biotechnology partners for co-development, licensing and commercialization of WPD401 and its broader targeted-oncology platform. The primary opportunity is WPD401 in recurrent glioblastoma, with potential expansion into newly diagnosed GBM, brain metastases and other receptor-positive tumors. WPD is particularly interested in partners with capabilities in ADC/PDC development, CNS oncology, innovative blood–brain barrier delivery, clinical development and global commercialization.

Organisation

WPD Pharmaceuticals SA

Company (SME/startup) / 中小企業・スタートアップ

Warszawa, Poland